Intracystic injection of OK-432: A new sclerosing therapy for cystic hygroma in children



Nine patients with cystic hygroma were treated with a new sclerosing therapy consisting of intracystic injection of OK-432 (group A Streptococcus pyogenes of human origin). Favourable results including complete regression in eight patients and marked regression in one were observed within 2–3 months without serious side-effects except for fever of 2–3 days' duration and local inflammatory reaction lasting for 3–4 days. Local inflammatory reaction did not cause any damage to the overlying skin and did not lead to scar formation.